Rain Oncology Inc
Change company Symbol lookup
Select an option...
RAIN Rain Oncology Inc
XPL Solitario Zinc Corp
DD Dupont De Nemours Inc
RLJ RLJ Lodging Trust
TTEXF Bullion Gold Resources Corp
FRLN Freeline Therapeutics Holdings PLC
PCQ PIMCO California Municipal Income Fund
WULF Terawulf Inc
USB-A US Bancorp
DBTX Decibel Therapeutics Inc
Go

Health Care : Pharmaceuticals |
Company profile

Rain Oncology Inc. is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. Its product candidate includes milademetan. Milademetan is an oral, small molecule inhibitor of the p53-mouse double minute 2 (p53-MDM2) complex that reactivates p53. The product candidate is being developed in patients with MDM2-dependent cancers. p53 acts as a regulator of various cellular processes. The activity of p53 is controlled and regulated by the inhibitory protein MDM2. MDM2 binds to p53, thereby inducing degradation and allowing normal cells to function properly. Milademetan, by binding MDM2 at the p53 interaction site, prevents the formation of the MDM2-p53 complex, allowing p53 reactivation and subsequent transcription of genes that trigger cancer cell cycle arrest or apoptosis and can be readily measured by increases in the pharmacodynamic marker MIC-1 (GDF15) in the blood.

Closing Price
$1.26
Day's Change
0.15 (13.51%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.38
Day's Low
1.20
Volume
(Above Average)
Volume:
7,425,740

10-day average volume:
6,410,504
7,425,740
  • Prev Close
    1.11
  • Today's Open
    1.24
  • Day's Range
    1.20-1.38
  • Avg Vol (10-day)
    6.4M
  • Last (time)
    4:00p ET 06/02/23
  • Last (size)
    105
  • 52-Wk Range
    0.9401 - 14.48
    LowHigh
  • (01/10/23 - 05/30/23)
    34.03%
  • 233.9%
  • Market Cap
    45.8M
  • Shares Outstanding
    36.4M
  • -2.61
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • --
  • 77.09
  • (% of float 05/15/23)
    5.37

Latest News

June 01, 2023
2:41 pm ET
Accesswire
May 31, 2023
11:45 am ET
Accesswire
May 30, 2023
4:35 pm ET
PR Newswire
8:30 am ET
Globe Newswire
May 28, 2023
7:46 pm ET
Accesswire
May 27, 2023
11:34 pm ET
Globe Newswire
May 26, 2023
9:52 pm ET
Accesswire
May 25, 2023
11:01 pm ET
Accesswire
9:47 pm ET
Newsfile
10:30 am ET
BusinessWire
May 24, 2023
10:00 pm ET
Accesswire
5:28 pm ET
BusinessWire
12:56 pm ET
Accesswire
May 23, 2023
6:00 pm ET
Accesswire
8:26 am ET
MarketWatch
May 22, 2023
11:40 am ET
PR Newswire
8:00 am ET
Globe Newswire
May 11, 2023
4:06 pm ET
Globe Newswire
April 24, 2023
8:00 am ET
Globe Newswire
April 05, 2023
8:00 am ET
Globe Newswire
March 21, 2023
5:50 am ET
Globe Newswire
March 09, 2023
4:05 pm ET
Globe Newswire
March 07, 2023
8:00 am ET
Globe Newswire
January 23, 2023
5:59 am ET
MarketWatch
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.